Alteminostat
Based on 1 publication(s) in Google Scholar
Alteminostat (CKD-581) is a potent HDAC inhibitor. Alteminostat inhibits the class I-II HDAC family via histone H3 and tubulin acetylation. Alteminostat can be used for lymphoma and multiple myeloma research.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.66%
- CAS No.: 1246374-97-9
- Formule: C27H36N6O3
- Masse moléculaire:492.61
-
Stockage:
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Epigenetics Compound Library
HY-L005
-
Histone Modification Research Compound Library
HY-L024
-
Anti-Cancer Compound Library
HY-L025
-
Clinical Compound Library
HY-L026
-
Anti-Aging Compound Library
HY-L034
-
Reprogramming Compound Library
HY-L039
-
Oxygen Sensing Compound Library
HY-L045
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Blood Cancer Compound Library
HY-L079
-
Anti-Liver Cancer Compound Library
HY-L101
-
Anti-Pulmonary Fibrosis Compound Library
HY-L125
-
Osteogenesis Compound Library
HY-L131
-
Heterocyclic Compound Library
HY-L138
-
Cell Death Library
HY-L162
-
Anti-Hematopathy Compound Library
HY-L171
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Clinical Compound Library Plus
HY-L026P
-
Bioactive Compound Library
HY-L001
-
Anti-Brain Cancer Compound Library
HY-L188
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Efficiency Gene Editing Compound Library
HY-L244
-
Lactylation Compound Library
HY-L249
Publications Citing Use of MedChemExpress (MCE) Alteminostat
More
Activité biologique
Alteminostat (CKD-581; 1 nM-10 μM; 72 hours) treatment potently reduces cell viability in all four lymphoma cell lines in a concentration-dependent manner. The IC50 values of Alteminostat in SU-DHL-4, OCI-LY1, SU-DHL-2, and U2932 cells are 1.31 nM, 36.91 nM, 1.18 nM, and 31.99 nM, respectively[1].
Alteminostat (CKD-581; 10-300 nM; 24 hours) treatment decreases the expression of BCL-6 as well as BCL-2 in cells[1].
Alteminostat (CKD-581; 30-300 nM; 24 h) treatment results in γH2AX accumulation and PARP1 cleavage in SU-DHL-4, OCI-LY1, SU-DHL-2, and U2932 cells. Alteminostat decreases the protein levels of BCL-XL and MCL-1 in a concentration-dependent manner in OCI-LY1 cells[1].
Alteminostat (CKD-581; 10-300 nM; 6 hours) treatment increases the acetylation of histone H3 in SU-DHL-2 cells. And tubulin acetylation also increased with 10 nM CKD-581. CKD-581 increased the acetylation of target molecules by inhibiting class I-II HDACs in lymphoma cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:SU-DHL-4, OCI-LY1, SU-DHL-2, and U2932 cells
-
Concentration:1 nM-10 μM
-
Incubation Time:72 hours
-
Result:Potently reduced cell viability in all four lymphoma cell lines in a concentration-dependent manner.
-
Cell Line:SU-DHL-4 and OCI-LY1 cells
-
Concentration:10 nM, 30 nM, 100 nM, 300 nM
-
Incubation Time:24 hours
-
Result:Decreased the expression of BCL-6 as well as BCL-2 in cells.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male NOD.CB17 SCID injected with SU-DHL-4 cells[1]
-
Dosage:20 mg/kg or 40 mg/kg
-
Administration:Intraperitoneal injection; twice a week; for 4 weeks
-
Result:Partially but significantly suppressed tumor growth.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1246374-97-9
-
Appearance Solid
-
Masse moléculaire 492.61
-
Formule C27H36N6O3
-
Color White to off-white
-
SMILES
O=C(N1CCN(C)CC1)N(CCCCCCC(NO)=O)C2=CC=C(C3=CC4=C(C=C3)C=NN4C)C=C2
-
Synonyms
CKD-581
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Cell Rep
Comprehensive mass spectrometry screening-derived atlas of HDAC inhibitors reveals histone-specific acetylation changes. [Abstract]2026 May 26;45(5):117289. PMID: 42030158
Solvant et solubilité
DMSO : 230 mg/mL (466.90 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureté et documentation
-
Fiche technique (273 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.0300 mL | 10.1500 mL | 20.3000 mL | 50.7501 mL |
| 5 mM | 0.4060 mL | 2.0300 mL | 4.0600 mL | 10.1500 mL | |
| 10 mM | 0.2030 mL | 1.0150 mL | 2.0300 mL | 5.0750 mL | |
| 15 mM | 0.1353 mL | 0.6767 mL | 1.3533 mL | 3.3833 mL | |
| 20 mM | 0.1015 mL | 0.5075 mL | 1.0150 mL | 2.5375 mL | |
| 25 mM | 0.0812 mL | 0.4060 mL | 0.8120 mL | 2.0300 mL | |
| 30 mM | 0.0677 mL | 0.3383 mL | 0.6767 mL | 1.6917 mL | |
| 40 mM | 0.0508 mL | 0.2538 mL | 0.5075 mL | 1.2688 mL | |
| 50 mM | 0.0406 mL | 0.2030 mL | 0.4060 mL | 1.0150 mL | |
| 60 mM | 0.0338 mL | 0.1692 mL | 0.3383 mL | 0.8458 mL | |
| 80 mM | 0.0254 mL | 0.1269 mL | 0.2538 mL | 0.6344 mL | |
| 100 mM | 0.0203 mL | 0.1015 mL | 0.2030 mL | 0.5075 mL |
Alteminostat Related Classifications
HY-109109 Related Classifications
Powered by Bioz